UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the date of December 19, 2023
Commission File Number 001-39124
Centogene N.V.
(Translation of registrant's name into English)
Am Strande
7
18055 Rostock
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F..X.. Form 40-F.....
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Centogene N.V.
On December 19, 2023, Centogene N.V. issued a press release
titled “CENTOGENE Announces Voting Results of Extraordinary General Meeting”
A copy of the press release is attached hereto as Exhibit 99.1.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: December 19, 2023
|
CENTOGENE N.V.
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jose Miguel Coego Rios |
|
|
Name: |
Jose Miguel Coego Rios |
|
|
Title: |
Chief Financial Officer |
Exhibit Index
Exhibit |
Description of Exhibit |
|
|
99.1 |
Press release dated December 19, 2023 |
Exhibit 99.1
CENTOGENE Announces
Voting Results of Extraordinary General Meeting
CAMBRIDGE, Mass. And ROSTOCK, Germany
and BERLIN, December 19, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven
answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting.
All voting items on the agenda, which included the adoption of Dutch statutory annual accounts for the financial year ended December
31, 2022, were passed by the requisite majority.
Peer Schatz, Chairman of the Supervisory
Board of CENTOGENE said, “We would like to thank all of our shareholders for their continued support of CENTOGENE’s mission
to deliver data-driven, life-changing answers to rare and neurodegenerative disease patients around the world.”
About CENTOGENE
CENTOGENE’s mission is to provide
data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate
multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision
medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease
states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.
Since our founding in 2006, CENTOGENE
has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and
CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic
datasets. This data is captured in our CENTOGENE Biodatabank, with over 800,000 patients represented from over 120 highly diverse countries,
over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more
than 285 peer-reviewed publications.
By translating our data and expertise
into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery,
development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.
To discover more about our products,
pipeline, and patient-driven purpose, visit www.centogene.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical
in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,”
“estimate,” “intend,” “project,” “plan,” “is designed to,” “potential,”
“predict,” “objective” and similar expressions and future or conditional verbs such as “will,” “would,”
“should,” “could,” “might,” “can,” and “may,” or the negative of these are
generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties,
and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different
from any future results, performance, or achievements expressed or implied by the forward- looking statements. Such risks and uncertainties
include, among others, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and
consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration,
our reliance on third parties and collaboration partners, including our ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance
on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our continued ongoing compliance with covenants linked to financial instruments, our requirement
for additional financing, and our ability to continue as a going concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating
to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on May 16,
2023, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events, or otherwise.
CONTACT
CENTOGENE
Melissa Hall
Corporate Communications
Press@centogene.com
Lennart Streibel
Investor Relations
IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024